Loading...
•
Dec 31, 2022
Avadel Q4 2022 Earnings Report
Avadel reported Q4 2022 financial results, highlighted by progress towards potential LUMRYZ commercialization and strategic financing.
Key Takeaways
Avadel Pharmaceuticals reported a net loss of $27.5 million for the fourth quarter of 2022. The company is preparing for the potential commercial launch of LUMRYZ and secured $200 million in capital to support the launch.
Filed an amendment to the FDA requesting final approval for LUMRYZ.
Received FDA authorization to import LUMRYZ in advance of final approval decision.
Secured $200 million of capital to fund the launch of LUMRYZ and extended the maturity of $96.2 million of convertible notes to 2027.
Launch preparations are on track to support the U.S. commercial launch of LUMRYZ.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...